Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities (Tables)

v3.23.1
Accrued Expenses and Other Current Liabilities (Tables)
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

 

 

March 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

Vaxcyte-related accrual under Vaxcyte Supply Agreement

 

$

5,274

 

 

$

4,830

 

CMO-related accrual

 

 

2,404

 

 

 

3,900

 

Clinical trials-related accrual

 

 

2,524

 

 

 

2,954

 

Other

 

 

2,191

 

 

 

3,080

 

Total accrued expenses and other current liabilities

 

$

12,393

 

 

$

14,764